Published in Ophthalmic Res on September 12, 2007
Ocular drug delivery. AAPS J (2010) 2.19
Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res (2010) 1.20
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis (2008) 1.15
Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res (2008) 1.07
Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol (2015) 1.05
Technical brief: subretinal injection and electroporation into adult mouse eyes. Mol Vis (2008) 0.95
Ocular drug delivery systems: An overview. World J Pharmacol (2015) 0.94
Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opin Drug Deliv (2011) 0.92
Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery. Recent Pat Nanomed (2012) 0.91
Pharmaceutical intervention for myopia control. Expert Rev Ophthalmol (2010) 0.90
Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis. AAPS PharmSciTech (2014) 0.87
Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol (2010) 0.85
Sonoporation enhances chemotherapeutic efficacy in retinoblastoma cells in vitro. Invest Ophthalmol Vis Sci (2011) 0.85
Topical Use of Angiopoietin-like Protein 2 RNAi-loaded Lipid Nanoparticles Suppresses Corneal Neovascularization. Mol Ther Nucleic Acids (2016) 0.82
Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol (2013) 0.82
Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application. Antimicrob Agents Chemother (2011) 0.81
Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. Drug Metab Dispos (2009) 0.80
In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment. J Ocul Pharmacol Ther (2010) 0.79
Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection. Pharm Res (2013) 0.78
Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes. Pharm Res (2012) 0.77
Sustained subconjunctival protein delivery using a thermosetting gel delivery system. J Ocul Pharmacol Ther (2010) 0.77
Delivery of intraocular triamcinolone acetonide in the treatment of macular edema. Pharmaceutics (2012) 0.75
Advances in drug delivery to the posterior segment. Curr Opin Ophthalmol (2015) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol (2011) 3.63
Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol (2008) 3.22
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 2.53
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res (2009) 2.25
Prospects for urinary proteomics: exosomes as a source of urinary biomarkers. Nephrology (Carlton) (2005) 1.77
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res (2006) 1.67
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood (2013) 1.56
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci (2011) 1.46
Isolation and purification of exosomes in urine. Methods Mol Biol (2010) 1.44
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
Biodegradable implants for sustained drug release in the eye. Pharm Res (2010) 1.20
A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res (2005) 1.18
Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci (2004) 1.17
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res (2002) 1.15
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res (2011) 1.14
Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci (2009) 1.13
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res (2010) 1.11
Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina (2006) 1.08
Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 1.06
Sarcoidosis in chronic granulomatous disease. Pediatrics (2006) 1.04
Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci (2007) 1.02
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol (2011) 0.99
Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol Vis Sci (2007) 0.99
A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci (2006) 0.98
Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin. AIDS (2004) 0.96
Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature. Surv Ophthalmol (2004) 0.94
Developing Bacillus spp. as a cell factory for production of microbial enzymes and industrially important biochemicals in the context of systems and synthetic biology. Appl Microbiol Biotechnol (2013) 0.91
Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm Res (2007) 0.91
Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann Biomed Eng (2005) 0.90
The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res (2005) 0.88
Novel drug delivery systems for retinal diseases. A review. Ophthalmic Res (2009) 0.87
Structure-based engineering of methionine residues in the catalytic cores of alkaline amylase from Alkalimonas amylolytica for improved oxidative stability. Appl Environ Microbiol (2012) 0.87
Comparison of cytotoxic and inflammatory responses of photoluminescent silicon nanoparticles with silicon micron-sized particles in RAW 264.7 macrophages. J Appl Toxicol (2009) 0.87
Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma. Ophthalmic Surg Lasers (2002) 0.86
Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol (2004) 0.86
Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release (2005) 0.85
Novel approaches to ocular drug delivery. Curr Opin Mol Ther (2004) 0.85
Measurement of internal tissue optical properties at ultraviolet and visible wavelengths: Development and implementation of a fiberoptic-based system. Opt Express (2008) 0.85
Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Curr Opin Ophthalmol (2009) 0.83
Gender differences in iridocorneal angle morphology: a potential explanation for the female predisposition to primary angle closure glaucoma in dogs. Vet Ophthalmol (2011) 0.82
Evaluation of clearance mechanisms with transscleral drug delivery. Invest Ophthalmol Vis Sci (2010) 0.82
Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin Cancer Res (2007) 0.82
Post-surgical scleritis associated with the ganciclovir implant. Ophthalmic Surg Lasers Imaging (2004) 0.82
Chemically surface modified gel (CSMG): an excellent enzyme-immobilization matrix for industrial processes. J Biotechnol (2006) 0.82
Photoassisted tuning of silicon nanocrystal photoluminescence. Langmuir (2007) 0.80
Low molecular weight hyaluronic acid effects on murine macrophage nitric oxide production. J Biomed Mater Res A (2010) 0.79
Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci (2005) 0.79
The safety and efficacy of chicken type II collagen on uveitis associated with juvenile rheumatoid arthritis. Ocul Immunol Inflamm (2002) 0.79
Erythrocyte survival is promoted by plasma and suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L). Blood (2002) 0.78
CMV retinitis in a patient with good syndrome. Ocul Immunol Inflamm (2005) 0.78
Conjugation of the photoluminescent silicon nanoparticles to streptavidin. Bioconjug Chem (2008) 0.78
Topical application of 0.005% latanoprost increases episcleral venous pressure in normal dogs. Vet Ophthalmol (2011) 0.78
Improvement of transglutaminase production by extending differentiation phase of Streptomyces hygroscopicus: mechanism and application. Appl Microbiol Biotechnol (2012) 0.78
Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis. AIDS (2004) 0.77
Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamido-triazole (CAI) and 2-methoxyestradiol (2ME2). Retina (2005) 0.77
Sustained subconjunctival protein delivery using a thermosetting gel delivery system. J Ocul Pharmacol Ther (2010) 0.77
Hydrolysis of wheat starch and its effect on the falling number procedure: mathematical model. Biotechnol Bioeng (2002) 0.77
A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. Invest Ophthalmol Vis Sci (2007) 0.77
Iridocorneal angle measurements in mammalian species: normative data by optical coherence tomography. Vet Ophthalmol (2012) 0.76
Extensive retinal neovascularization as a late finding in human immunodeficiency virus-infected patients with immune recovery uveitis. Clin Infect Dis (2003) 0.76
New corticosteroid-eluting porous polyethylene implant for the management of lower eyelid retraction: a pilot study. Ophthal Plast Reconstr Surg (2006) 0.76
Intravitreal injection of triamcinolone acetonide for immune recovery uveitis. Retina (2006) 0.76
Estimation of the differential pressure at renal artery stenoses. Magn Reson Med (2004) 0.75
Immobilized thermolysin for highly efficient production of low-molecular-weight protamine--an attractive cell-penetrating peptide for macromolecular drug delivery applications. J Biomed Mater Res A (2011) 0.75
Defining critical inflammatory parameters for endotoxin impurity in manufactured alginate microcapsules. J Biomed Mater Res B Appl Biomater (2009) 0.75
The effect of topical latanoprost on anterior segment anatomic relationships in normal dogs. Vet Ophthalmol (2012) 0.75
Small-angle neutron scattering measurement of silicon nanoparticle size. Nanotechnology (2008) 0.75
Enzyme stabilization and immobilization by sol-gel entrapment. Methods Mol Biol (2011) 0.75
Electrochemical reduction synthesis of photoluminescent silicon nanocrystals. Langmuir (2009) 0.75